Case Study

Elucidating a Metabolic Signature that Explains Gut-Related Changes in Human Energy Balance

Metabolon’s Short Chain Fatty Acids (SCFA) Targeted Panel provides an improved understanding of the relationship between the gut microbiome and human energy balance.

In this comprehensive study, researchers delved into the intricate relationship between the gut microbiome and human energy balance, a critical factor in overall health.¹ Using Metabolon’s Short Chain Fatty Acids Targeted Panel, they analyzed fecal and serum samples from individuals on different diets, shedding light on how the gut microbiome influences energy balance.

Talk With An Expert About Your Project

Elucidating a Metabolic Signature that Explains Gut-Related Changes in Human Energy Balance

The Challenge: Exploring the Role of the Gut Microbiome in Human Energy Balance

Human energy balance is a crucial factor in maintaining overall health and well-being. It refers to the equilibrium between energy intake (calories consumed), energy expenditure (calories burned through metabolic processes), and energy output (energy excreted through feces and urine from undigested food). Maintaining a healthy energy balance is essential in various aspects of health, including weight management, cardiovascular health, and immune function. The gut microbiome is emerging as a key modulator of human energy balance. Despite this knowledge, studies to date lack a comprehensive quantitative evaluation of the contribution of the gut microbiome to the entire energy balance equation. Insights into modifiable factors in the microbiome might help manage conditions related to energy balance. To help fill this knowledge gap, this study used a multi-omics approach to profile fecal samples and sera from individuals in a metabolic ward. The insights from this study reveal the complex intersection of host-diet-gut microbiome factors that modulate energy balance and possibly human health.

Metabolon’s Insight: Microbiome-Derived Metabolites and the Host’s Energy Balance

The research group used Metabolon’s Short Chain Fatty Acids Targeted Panel to profile fecal and serum samples from individuals on a Western Diet (WD) or a microbiome-enhanced diet (MBD).¹ Using Metabolon’s technology outputs, the researchers were able to establish an improved understanding of the relationship between the gut microbiome and human energy balance.

The Solution: Changes in Energy Balance Can Be Attributed to SCFAs

This research team conducted a controlled feeding study to detect energy balance changes in response to the diet intervention. They used an MBD, a diet designed to feed and modulate the colonic gut microbiome. They found that compared to the WD, the MBD increased daily fecal energy output consisting of undigested food. Therefore, the MBD produced a significant decrease in host metabolizable energy compared to the WD, consequently reducing the energy available to the host.

Next, they evaluated the microbial phenotype associated with host energy balance. 16S rRNA sequencing of the participants’ gut microbiome revealed that the MDB changed the microbiome composition, increasing the abundance of SCFA-producing bacteria. They found that an increase in fecal and serum SCFA content, including acetic acid, propionic acid, and butyric acid paralleled diet-induced changes in microbial composition. Conversely, the WD starved the gut microbes because the host had digested and absorbed more metabolizable energy in the gastrointestinal tract. Changes in the microbiome due to the MBD were accompanied by a modest weight/body composition change and significant changes in the host’s enteroendocrine system.

The Outcome: Harnessing the Power of the Microbiome for Personalized Medicine

This study integrated metabolomics and profiling of the gut microbiome to understand how the gut microbiome modulates energy balance. Metabolon helped elucidate the complex host-diet-microbiome interplay that modulates human energy balance. The research team found that the gut microbiome can serve as a target for personalized medicine. In this case, optimizing SCFA production through diet could promote a favorable energy balance and improve overall health.

References

1. Corbin KD, Carnero EA, Dirks B, et al. Host-diet-gut microbiome interactions influence human energy balance: a randomized clinical trial. Nat Commun. May 31 2023;14(1):3161. doi:10.1038/s41467-023-38778-x

Related Case Studies

See All Case Studies

Metabolomics finds PanK4 to be an Important Regulator of Glucose Uptake and Lipid Metabolism

Find out more $

Metabolomics provides insight into the pathology of sudden infant death syndrome and identifies biomarker candidates

Find out more $

Metabolomics Reveals Beneficial Changes to Metabolite Profiles During Diabetes Remission

Find out more $

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.